Epicatelean® (Epicatechin) Benefits

Epicatechin, a flavonoid predominantly sourced from green tea (Camellia sinensis) and dark chocolate, is accompanied by epigallocatechin as key catechins. These compounds offer a spectrum of health advantages, mitigating the likelihood of diabetes and heart-related conditions. Their therapeutic properties encompass lowering lipid levels, curbing inflammation, neutralizing oxidative stress, preventing cancer, and safeguarding cells. These natural flavonoids can be utilized independently or in tandem with other medications and antibiotics, paving the way for innovative phytopharmaceuticals.

Epigallocatechin (EGC), the predominant and potent polyphenol in Spondias mombin, is attributed to its extensive health benefits supported by clinical, animal, and cellular studies. It exhibits antimicrobial capabilities against drug-resistant organisms by disrupting cellular structures and processes, including the cell membrane, biosynthesis, signaling, and DNA integrity. EGC's antioxidant prowess is pivotal in managing chronic oxidative stress-related conditions, including heart ailments, neurodegenerative disorders, and cancer. Studies have shed light on its heart-protective and blood pressure-lowering effects, preventing blood clots, reducing cholesterol levels, and curbing lipid oxidation.

Laboratory experiments utilizing albino rats have shown that EGC diminishes cancer risk by interacting with crucial proteins, influencing signaling pathways, and inducing growth arrest through apoptosis or by inhibiting angiogenesis and metastasis. It also decelerates cognitive decline and neurodegenerative conditions such as Alzheimer's and Parkinson's, as evidenced by research on mice. EGC's anti-obesity effects are realized through promoting fat metabolism and weight reduction. It has been shown in animal studies to be instrumental in averting the onset of both types of diabetes by enhancing lysosomal function and modulating autophagy and liver lipid clearance, thanks to its anti-steatotic characteristics. EGC exhibits anti-inflammatory effects in a dose-dependent fashion by diminishing inflammatory mediators, and its anti-allergic properties are marked by the suppression of mast cell activation and the expression of high-affinity IgE receptors.

Epicatelean® (Epicatechin) 

Antioxidative Effects

Epicatechin's antioxidant prowess lies in its ability to neutralize various free radicals, including reactive oxygen and nitrogen species as well as superoxide. Research on the liver-protective properties of Spondias mombin extract has demonstrated its capacity to quench free radicals, thus shielding the liver from oxidative stress that could potentially lead to liver cancer. The presence of epicatechin and other polyphenols in the body reduces the oxidizability of low-density lipoproteins, averting the onset of atherosclerosis.

In the context of HIV, proteins such as Tat and gp120 are recognized for their neurotoxic effects, which are mediated through the activation of immune cells and culminate in oxidative stress. Epicatechin offers neuroprotection by mitigating the oxidative stress induced by these neurotoxic HIV proteins. Preemptive administration of epicatechin can avert liver and testicular harm caused by gamma radiation, which is typically due to the oxidative stress from free radicals generated by radiation exposure. Its radioprotective properties are particularly beneficial for individuals undergoing radiotherapy.

The Hepatitis C virus (HCV), an RNA virus with chronic infections affecting approximately 160 million people worldwide, is linked to severe health conditions like cirrhosis, liver failure, and liver cancer. HCV spreads through cell-to-cell transmission, involving a complex process of endocytosis and viral-host membrane fusion. EGC has been shown to impede this transmission by inhibiting the initial attachment of HCV to host cells, thereby hindering viral entry and RNA replication. A single dose of EGC, ranging from 50 to 1,600mg, has been identified as both effective in inhibiting HCV and safe for human consumption. Furthermore, EGC contributes to the disruption of lipid droplet formation and lipoprotein secretion in liver cells, processes that are essential for the HCV life cycle.

Epigallocatechin (EGC) exerts a multifaceted influence on the HIV life cycle, targeting key stages from initial cell attachment and viral entry to the replication process and mRNA transcription. It impedes the infectivity of the virus by interacting with the viral envelope's surface, causing structural alterations to the phospholipids and leading to the disintegration of the viral particle. The initial binding of the gp120 envelope protein to the CD4 receptor on T-helper cells is a critical step in HIV-1 infection, which EGC can thwart by blocking the gp120-CD4 interaction, thereby preventing viral attachment.

This catechin also hinders the functionality of reverse transcriptase, an enzyme pivotal in converting viral RNA to DNA, and the integrase enzyme, which integrates this newly synthesized DNA into the host's genome. EGC further suppresses the production of new virus particles from infected cells and curbs the expression levels of viral mRNA. It has been shown to physically alter and aggregate the virus, impeding its ability to adhere to Madin-Darby Canine Kidney (MDCK) cells. Additionally, EGC can halt the proliferation of the influenza virus by inhibiting the acidification of intracellular compartments such as endosomes and lysosomes, and by binding to the hemagglutinin protein, it obstructs viral entry.

Adenoviruses, non-enveloped viruses with a nucleocapsid and a double-stranded DNA genome, are another target of EGC's antiviral activity. They account for a significant proportion of upper respiratory infections in children. Research by Weber and colleagues has demonstrated that EGC can neutralize adenoviruses and suppress the activity of viral proteases. It is particularly effective during the transition from the early to the late phase of infection and can inhibit the progression and intracellular growth of the virus during its late stages.

In summary, EGC and epicatechin stand out as remarkable natural therapeutic agents. There is a compelling need to invest further in their development as sustainable pharmaceuticals for the prevention and management of a wide range of diseases and complications.

References

1. Brown J, Arthur, J. Selenium, selenoproteins and human health: a review. Public Health Nutrition. 2001. (2B): 593-9.
2. Nakayam M, Suzuki K, Toda M, Okubo S, Hara Y, Shimamura T. Inhibition of the infectivity of influenza virus by tea polyphenols. Antivir Res. 1993;21:289-299.
3. Imanishi N, Tuji Y, Katada Y, Maruhashi M, Konosu S, Mantani N, Terasawa K, Ochiai H. Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells. Microbiol Immunol. 2002;46:491-494.
4. Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antivir Res 2005;68:66-74.
5. Springbob K, Springbob K, Toni M. Introduction to the different classes of natural products. In Lanzotti, Virginia. 2009. Plant-derived Natural Products: Synthesis, Function and Application. Springer. P.3. ISBN 9780387854977.
6. Kähkönen MP, Hopia AI, Vuorela HJ, Rauha JP, Pihlaja K, Kujala TS, et al. Antioxidant activity of plant extracts containing phenolic compounds. J Agric Food Chem. 1999;47:3954-62.
7. Osakabe N, Babab S, Yasuda A, Iwamoto T, Kamiyama M, Takahisa T, Kondo K. Dose-response study of daily cocoa intake on the oxidative susceptibility of low-density lipoprotein in healthy human volunteers. J Health Sci. 2004;50(6):679-684
8. Nath S, Bachani M, Harshavardhana D, Steiner JP. Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway. J Neurovirol .2012; DOI 10.1007/s13365-012-0122-1.
9. Huang Q, Wu LJ, Tashiro SI, Onodera S, Ikejima T. Elevated levels of DNA repair enzymes and antioxidative enzymes by (1)-catechin in murine microglia cells after oxidative stress. J Asian Nat Prod Res. 2006;8:61-71.
10. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011:17:107-115.
11. Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V et al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology. 2012;55:720- 9.